The results suggested that IL-6 was not different between the trial groups and control groups in RA treatment (MD = −6.36, 95% CI (−18.74, 6.02), P < 0.0001) (Figure 6(b)). The gene discussed is IL6; the disease is rheumatoid arthritis.